Application of the Latest Immuno-Oncology Developments to the Treatment of Urothelial Cancer

Join us for this dynamic, IME symposium where bladder cancer experts will review the evolving role of immunotherapy in the treatment of bladder cancer, including patient case discussions and discussion of new data.

Sign up now!

Thank you for your interest in attending the Clinical Care Options (CCO) Webinar, “Application of the Latest Immuno-Oncology Developments to the Treatment of Urothelial Cancer.”

Please note that this live Webinar will feature the expert faculty, along with interactivity, evidence-based content, and panel discussions. When participating in a live Webinar, you will be able to text questions directly to the faculty and the planned agenda allows time for the faculty to discuss and answer submitted questions.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Thank you,
CCO Member Services


Current treatment landscape for first line urothelial cancer

Challenges in selecting first-line therapy for urothelial carcinoma – Professor Powles

  • Current first-line therapy guidelines and recommendations
  • Clinical scenarios in which ICI therapy is the optimal treatment course
    • Cisplatin-ineligible patients
    • PD-L1 expression and agent specific assays and expression thresholds

Current treatment landscape for second and subsequent lines of therapy in urothelial cancer – Dr. Ravaud

  • Sequencing strategies, considerations, and challenges

Future directions in metastatic and earlier stages of urothelial cancer and maintenance therapy after initial chemotherapy – Professor Powles / Dr. Ravaud




Date / Time
Event Details


Program Director
Thomas Powles, MBBS, MRCP, MD

Deputy Centre Lead
Centre for Experimental Cancer Medicine
Barts Cancer Institute
Queen Mary University of London
Professor of Urology Cancer
Director of Barts Cancer Centre
Department of Cancer
St Bartholomew's Hospital (Barts Health NHS Trust)
London, United Kingdom

Alain Ravaud, MD, PhD

Professor of Medical Oncology
Head of Department of Medical Oncology
Bordeaux University Hospital
Bordeaux, France

This educational activity is not certified for CME/CE credit

Goal Statement
The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the use of the current and evolving immuno-oncology–based standard of care, first-line treatments, and sequencing in the care of their patients with urothelial cancer.

Target Audience
This targeted program is designed to both inspire and instruct urologists, medical oncologists, and other healthcare providers caring for patients with urothelial cancer (UC) around the world and especially in Europe (Big 5 EU and Switzerland) and South America (Argentina). The identified target audience will benefit from this education by gaining the knowledge necessary to integrate the use of immune checkpoint inhibitors (ICI) into the treatment of advanced UC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate checkpoint inhibitor therapies into practice to optimize the care of patients with advanced urothelial carcinoma, taking into consideration the available evidence and patient and disease characteristics
  • Evaluate biomarkers that accurately predict treatment response and assist in patient selection for personalized therapy
  • Plan therapy for patients with urothelial carcinoma and disease progression during or following platinum-containing chemotherapy and/or immune checkpoint inhibitor therapy
  • Discuss ongoing clinical trials investigating targeted systemic therapies and immune checkpoint inhibitor–based combinations for patients across the urothelial carcinoma disease spectrum
  • Incorporate guideline and expert recommendations to optimally manage adverse events associated with the use of immune checkpoint inhibitors


This educational activity is not certified for CME/CE credit.